Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

British journal of haematology·2026
Same author

Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma.

Leukemia & lymphoma·2026
Same authorSame journal

Modified short-course fludarabine-based conditioning regimen for salvage cord blood transplantation after graft failure.

International journal of hematology·2026
Same author

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Blood advances·2026
Same author

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Blood advances·2026
Same author

[Overview].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Related Experiment Video

Updated: Jun 5, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

9.9K

A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system:

Hironori Arai1,2, Naoko Hosono3, SungGi Chi2

  • 1Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.

International Journal of Hematology
|December 16, 2024
PubMed
Summary
This summary is machine-generated.

The HM-SCREEN-JAPAN02 study found that a cancer genome panel is clinically useful for acute myeloid leukemia (AML) treatment. It identified TP53 and NRAS mutations linked to higher mortality risk.

Keywords:
Acute myeloid leukemiaGenomic testingNext-generation sequencing

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 5, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

9.9K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Acute myeloid leukemia (AML) treatment can be improved by understanding its genetic landscape.
  • Multicenter collaborative projects are crucial for evaluating novel diagnostic tools in clinical practice.

Purpose of the Study:

  • To assess the clinical utility of a cancer genome panel in AML treatment within the HM-SCREEN-Japan project.
  • To evaluate the efficiency and speed of genomic testing for AML patients.

Main Methods:

  • Utilized the Amoy Myeloid Panel® targeting 53 genes for genomic testing on bone marrow or peripheral blood samples.
  • Included 179 tests from 145 AML patients, allowing for multiple time points to track clonal evolution.
  • Employed the HANDLE system for rapid sequencing and annotation, with a median turnaround time of 8 days.

Main Results:

  • Identified diverse mutation patterns, including acquired resistance mutations and persistent pathogenic mutations post-remission.
  • TP53 and NRAS mutations were significantly associated with an increased risk of death (HR=3.98 and 5.50, respectively).
  • 63% of physicians found the genomic panel clinically useful for risk assessment and guiding hematopoietic stem cell transplantation decisions.

Conclusions:

  • The cancer genome panel demonstrates significant clinical utility in managing AML patients.
  • Genomic profiling aids in risk stratification and informs critical treatment decisions, including transplantation.
  • Rapid genomic testing facilitates timely clinical management and personalized treatment strategies for AML.